Sanofi-Aventis will be expanding into generics, says the Wall Street Journal, while cutting its research and development. The generic group will be reshuffled to focus on emerging markets where drug sales are on the rise. The Health Blog adds that Sanofi recently bought two Latin American generic-drug companies as well as a Czech one.